ZVRA - Zevra Therapeutics Inc
IEX Last Trade
7.65
0.260 3.399%
Share volume: 436,157
Last Updated: Fri 30 Aug 2024 09:59:57 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.87%
PREVIOUS CLOSE
CHG
CHG%
$7.39
0.26
3.52%
Fundamental analysis
25%
Profitability
8%
Dept financing
27%
Liquidity
75%
Performance
30%
Performance
5 Days
6.55%
1 Month
39.09%
3 Months
63.81%
6 Months
11.52%
1 Year
44.34%
2 Year
42.72%
Key data
Stock price
$7.65
DAY RANGE
N/A - N/A
52 WEEK RANGE
$3.89 - $8.44
52 WEEK CHANGE
$0.42
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Travis Mickle
Region: US
Website: http://www.kempharm.com/
Employees: 36
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: http://www.kempharm.com/
Employees: 36
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
kempharm is a biopharmaceutical company focused on the discovery and development of new chemical entities (nces) to treat serious medical conditions through its proprietary and broadly applicable ligand activated therapy (lat) approach. the company utilizes its lat technology to generate improved prodrug versions of fda approved drugs in the high needs areas of pain, adhd and other cns diseases.
Recent news